Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder   Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patients. PORTICO plans to recruit 188 patients.   MADRID, Spain and BOSTON, July 05, 2023 (GLOBE NEWSWIRE) -- ..
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 (tyrosine kinase 2..
Lunit's AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists' Diagnostic Determination - Published in Radiology A recent study conducted by Seoul National University Hospital provides strong evidence that a high-accuracy AI model improves radiologists' chest X-ray analysis performance. Lunit, a global provider of AI-powered cancer diagnostics solutions, announced the publ..
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company, announced that it anticipates releasing topline results from two Phase 3 clinical trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea. The results are e..
Abeona Therapeutics Inc. (Nasdaq: ABEO) has successfully raised $25 million through a registered direct offering under Nasdaq rules. The funds were primarily raised to support the launch preparations for the Company's EB-101 Biologics License Application (BLA) submission and potential approval. Abeona entered into definitive agreements with existing institutional investors, issuing and selling 3..
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial   Positive high-level results from the TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (..
Fresenius Kabi, a global healthcare company specializing in medicines and technologies, has announced the availability of its first immunology biosimilar, IDACIO® (adalimumab-aacf), in the United States. IDACIO® is indicated for use in the treatment of chronic autoimmune diseases and is a biosimilar to Humira® (adalimumab). It is available in a self-administered prefilled syringe and pre-filled ..
Labcorp, a global leader in laboratory services, has successfully completed the spin-off of Fortrea, an independent Contract Research Organization. Fortrea will now offer clinical trial management and technology solutions to pharmaceutical and biotechnology organizations on a global scale. The company is set to begin trading on the NASDAQ Stock Market under the symbol "FTRE." Expressing his grat..
